Quadrant Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Quadrant Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$2.42M	Buy	37,691 +4,587	+14%	+$263K	1.09%	42
2019 Q3	$1.68M	Buy	33,104 +3,837	+13%	+$180K	0.83%	57
2019 Q2	$1.33M	Buy	29,267 +2,117	+8%	+$98.6K	0.7%	58
2019 Q1	$1.29M	Buy	+27,150	New	+$1.35M	0.72%	55

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Quadrant Capital Management's BMY Position: Q4 2019 in Review

Quadrant Capital Management increased its Bristol-Myers Squibb (BMY) stake by 14% in Q4 2019, buying an estimated $263K and bringing the position to 37,691 shares worth $2.42M. The position accounts for 1.09% of the portfolio, ranked #42.

Quadrant Capital Management first reported a position in BMY in Q1 2019 and has held it in 4 quarters since. 2,217 funds tracked by Wall St. Rank hold BMY as of Q4 2019.

Quadrant Capital Management held 37,691 shares of Bristol-Myers Squibb worth $2.42M as of Q4 2019.
Quadrant Capital Management bought 4,587 Bristol-Myers Squibb shares in Q4 2019, an estimated $263K.
Bristol-Myers Squibb made up 1.09% of Quadrant Capital Management's portfolio in Q4 2019, its #42 holding.
Quadrant Capital Management first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 4 quarters since.
2,217 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2019.

Based on Quadrant Capital Management's 13F filing for Q4 2019, filed 29 Jan 2020.